1. Fleckenstein A et al. Uterus relaxation by highly potent Ca plus, plus-antagonistic inhibitors of electro-mechanical coupling such as Isoptin (verapamil, iproveratril), compound D 600 and Segontin (prenylamine). Experiments on the isolated virgin rat uterus. Klin Wochenschr 1971; 49 (1): 32–41.
2. Toyo-Oka T, Nayler W Third generation calcium entry blockers. Blood Press 1996; 5 (4): 206–8.
3. Руководство по артериальной гипертонии. М.: Медиа Медика, 2005.
4. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300.
5. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Российские рекомендации (второй пересмотр). Комитет экспертов Всероссийского научного общества кардиологов. Секция артериальной гипертонии ВНОК. Москва, 2004 г. Прил. к журн. "Кардиоваскул. тер. и профилак".
6. Чазова И.Е., Ратова Л.Г. Антагонисты кальция в лечении артериальной гипертонии (исследование ЭТНА). Системн. гипертензии. 2005; 1: 25–8.
7. Julius S, Kjeldsen SE at al. for VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT). JAMA 2002; 288: 2981–97.
9. Nissen SE, Tuzcu EM et al for CAMELOT investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–26.
10. Dahlof B, Sever PS et al. for ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
Авторы
И.Е.Чазова, Л.Г.Ратова от имени исследователей ЭТНА Плюс
Российский кардиологический научно-производственный комплекс Росздрава, Институт кардиологии им. А.Л.Мясникова, Москва